Time filter

Source Type

Yang Q.,Shandong University of Traditional Chinese Medicine | Yang Q.,Rizhao City Hospital of Traditional Chinese Medicine | Yang Q.,Shandong Academy of Chinese Medicine | Sun R.,Shandong Academy of Chinese Medicine
Chinese Traditional and Herbal Drugs | Year: 2016

To evaluate the clinical effect and safety of Xinkeshu Tablets on the double heart disease in coronary heart disease with depression systematically. The relative randomized controlled trials about Xinkeshu Tablets in the treatment of double heart disease in coronary heart disease with depression from 1979 to 2015 were searched in database like CNKI, WanFang data, CBM, Embase, Pubmed, and Cochrane Library. Studies were screened, data were extracted, and methodological quality was evaluated. Meta-analysis was then performed using Review Manager 5.1 software. Totally 11 kinds of studies and 961 patients were involved in this study. Xinkeshu Tablets combined with conventional Western medicine therapy was superior to pure conventional Western medicine therapy in clinical effect of coronary heart disease and improve of HAMD scores with the RR of 1.15 (1.07, 1.23) and 1.39 (1.07, 1.79) respectively. On the basis of available evidence, Xinkeshu Tablets combined with conventional Western medicine therapy has a certain effect on the double heart disease in coronary heart disease with depression, but more clinical study with big samples and high quality should be done to confirm the efficacy and safety. © 2016, Editorial Office of Chinese Traditional and Herbal Drugs. All right reserved.


Xue H.,Shandong University | Xue H.,Rizhao City Hospital of Traditional Chinese Medicine | Xue H.,National Research Center for Assisted Reproductive Technology and Reproductive Genetics | Xue H.,The Key Laboratory for Reproductive Endocrinology of Ministry of Education | And 15 more authors.
Journal of Assisted Reproduction and Genetics | Year: 2016

Purpose: The objective of this study was to evaluate the association between single-nucleotide polymorphisms (SNPs) rs2197076 and rs2241883 in fatty acid-binding protein 1 (FABP1) gene and polycystic ovary syndrome (PCOS). Methods: The two alleles rs2197076 and rs2241883 in FABP1 gene in 221 PCOS women and 198 normal women were amplified and sequenced. Allele frequency comparison was performed between the PCOS and control groups, and genotype-phenotype correlation analysis was performed using dominant and recessive models to assess the association of FABP1 and the main features of PCOS. Results: Allele frequency analyses showed a strong association of SNPs rs2197076 and rs2241883 of FABP1 gene with PCOS (P < 0.001). The additive, dominant, and recessive genotype model analyses further supported this association even after adjusting for age and body mass index (BMI). The minor allele frequency (MAF) of rs2241883 in obese PCOS women was less than that in obese control women. Further genotype-phenotype correlation analysis showed that SNP rs2197076 had a stronger association with the main features of PCOS than SNP rs2241883. Conclusion: In the association of SNPs in FABP1 gene with PCOS, rs2197076 was more closely associated with its main features than rs2241883 and seemed to play a more important role in the pathogenesis of PCOS. © 2015, Springer Science+Business Media New York.


Shi H.-T.,Fudan University | Chu H.-X.,Qingdao University | Gu W.,Capital Medical University | Cai X.-Y.,Jiangxi Provincial Peoples Hospital | And 11 more authors.
International Journal of Cardiology | Year: 2016

Background Second-generation drug-eluting stents (DESs) have become increasingly popular devices for patients with saphenous vein graft (SVG) disease. Second-generation DESs were designed to have more safety and efficacy than first-generation DES, but clinical outcomes in SVG disease remain conflicting. Methods and results Randomized controlled trials (RCTs) were identified when comparing second- versus first-generation DESs in SVG disease. The main endpoint was all-cause death. The time of follow-up was at least 30 days. The secondary endpoints were major adverse cardiovascular events (MACEs), target vessel revascularization (TVR), target lesion revascularization (TLR), myocardial infarction (MI), and stent thrombosis. These endpoints were assessed at 30 days, 12 months and 24 months. Four RCTs with 1077 SVG patients undergoing the implantation of DES were collected in the current meta-analysis. As a result, second-generation DES-treated patients had the significantly lower MACE rates at 12 months (P = 0.03; OR: 0.69, 95% CI: 0.49,0.97). No differences in two groups were seen in all-cause death, MI, TVR, stent thrombosis and TLR. Conclusions Our limited evidence indicated that, second-generation DES in SVG patients, compared with first-generation DES, offered similar levels of safety, but were more effective than the former one. © 2016 Elsevier Ireland Ltd.


Zhang S.,Fudan University | Xue H.,Rizhao City Hospital of Traditional Chinese Medicine | Chen Q.,Taishan Medical University
Oncotarget | Year: 2016

There is currently no standard treatment for metastatic urothelial cancer after failure of cisplatin-based therapy. The present retrospective study investigated the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOX) in locally advanced or metastatic urothelial cancer patients following cisplatin-based treatment. Thirty-three patients who had received one or two cisplatin-based regimens were treated with oxaliplatin (85 mg/m2) as a 2-h infusion on day 1, LV (200 mg/m2) as a 2-h infusion followed by bolus 5-FU (400 mg/m2) on day 1, or a 44-h continuous 5-FU (1,200 mg/m2) infusion. Patients were a mean of 67 years old with two involved organs. Metastases were mostly in the lung (43%), lymph nodes (51%) and liver (46%). Based on an intention-to-treat analysis, nine patients achieved a partial response, with an overall response rate of 27%. Eight (24%) patients had stable disease. Mean progression-free survival was 3 months and mean overall survival was 6.1 months. Toxicity was mild to moderate with grade 3 or 4 neutropenia, thrombocytopenia and neuropathy occurring in 5 (15%), 4 (12%) and 2 (6%) patients, respectively. This study demonstrated that oxaliplatin plus 5-FU/LV was a well-tolerated second-line regimen with moderate activity in patients pretreated with cisplatin-based therapeutics.


PubMed | Fudan University, Rizhao City Hospital of Traditional Chinese Medicine and Taishan Medical University
Type: Journal Article | Journal: Oncotarget | Year: 2016

There is currently no standard treatment for metastatic urothelial cancer after failure of cisplatin-based therapy. The present retrospective study investigated the efficacy and safety of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOX) in locally advanced or metastatic urothelial cancer patients following cisplatin-based treatment. Thirty-three patients who had received one or two cisplatin-based regimens were treated with oxaliplatin (85 mg/m2) as a 2-h infusion on day 1, LV (200 mg/m2) as a 2-h infusion followed by bolus 5-FU (400 mg/m2) on day 1, or a 44-h continuous 5-FU (1,200 mg/m2) infusion. Patients were a mean of 67 years old with two involved organs. Metastases were mostly in the lung (43%), lymph nodes (51%) and liver (46%). Based on an intention-to-treat analysis, nine patients achieved a partial response, with an overall response rate of 27%. Eight (24%) patients had stable disease. Mean progression-free survival was 3 months and mean overall survival was 6.1 months. Toxicity was mild to moderate with grade 3 or 4 neutropenia, thrombocytopenia and neuropathy occurring in 5 (15%), 4 (12%) and 2 (6%) patients, respectively. This study demonstrated that oxaliplatin plus 5-FU/LV was a well-tolerated second-line regimen with moderate activity in patients pretreated with cisplatin-based therapeutics.


PubMed | Fudan University, Capital Medical University, Jiangxi Provincial Peoples Hospital, Rizhao City Hospital of Traditional Chinese Medicine and Qingdao University
Type: | Journal: International journal of cardiology | Year: 2016

Second-generation drug-eluting stents (DESs) have become increasingly popular devices for patients with saphenous vein graft (SVG) disease. Second-generation DESs were designed to have more safety and efficacy than first-generation DES, but clinical outcomes in SVG disease remain conflicting.Randomized controlled trials (RCTs) were identified when comparing second- versus first-generation DESs in SVG disease. The main endpoint was all-cause death. The time of follow-up was at least 30days. The secondary endpoints were major adverse cardiovascular events (MACEs), target vessel revascularization (TVR), target lesion revascularization (TLR), myocardial infarction (MI), and stent thrombosis. These endpoints were assessed at 30days, 12months and 24months. Four RCTs with 1077 SVG patients undergoing the implantation of DES were collected in the current meta-analysis. As a result, second-generation DES-treated patients had the significantly lower MACE rates at 12months (P=0.03; OR: 0.69, 95% CI: 0.49,0.97). No differences in two groups were seen in all-cause death, MI, TVR, stent thrombosis and TLR.Our limited evidence indicated that, second-generation DES in SVG patients, compared with first-generation DES, offered similar levels of safety, but were more effective than the former one.

Loading Rizhao City Hospital of Traditional Chinese Medicine collaborators
Loading Rizhao City Hospital of Traditional Chinese Medicine collaborators